[Optimization of treatment options through a multidisciplinary approach for advanced hormone refractory prostate carcinoma].
Dogliotti
Luigi
L
SCDU Oncologia Medica, ASO San Luigi Gonzaga, Orbassano, Torino.
Mosca
Alessandra
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077143:Docetaxel; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000401:mortality / Q000628:therapy*; D043823:Taxoids / Q000627:therapeutic use; D017211:Treatment Failure
D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D008942:Mitoxantrone; D011241:Prednisone